Review of human rabies prophylaxis and treatment

Critical Care Nursing Clinics of North America

Volumn 25, Issue 2, 2013, Pages 225-242

  Weant, Kyle A ^a   Baker, Stephanie N ^b,c  

^a NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b UK Health Care ^*  (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antivirals; Human rabies; Human rabies immune globulin; Immunizations; Lyssavirus; Rabies; Rabies vaccine; Rabies virus

Indexed keywords

ANIMAL; DISEASE CARRIER; DRUG SURVEILLANCE PROGRAM; HUMAN; INCUBATION TIME; PALLIATIVE THERAPY; RABIES; REVIEW; SALIVA; UNITED STATES; VIROLOGY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; DISEASE VECTORS; HUMANS; INFECTIOUS DISEASE INCUBATION PERIOD; PALLIATIVE CARE; RABIES; SALIVA; UNITED STATES;

EID: 84878106408     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccell.2013.02.001     Document Type: Review

References (100)

1. Botvinkin A.D., Poleschuk E.M., Kuzmin I.V., et al. Novel lyssaviruses isolated from bats in Russia. Emerg Infect Dis 2003, 9:1623-1625.
2. Fooks A.R., Brookes S.M., Johnson N., et al. European bat lyssaviruses: an emerging zoonosis. Epidemiol Infect 2003, 131:1029-1039.
3. World Health Organization Rabies fact sheet 2012, World Health Organization, Geneva, Switzerland.
4. Jackson A.C. Recovery from rabies. N Engl J Med 2005, 352:2549-2550.
5. Anderson L.J., Nicholson K.G., Tauxe R.V., et al. Human rabies in the United States, 1960 to 1979: epidemiology, diagnosis, and prevention. Ann Intern Med 1984, 100:728-735.
6. Held J.R., Tierkel E.S., Steele J.H. Rabies in man and animals in the United States, 1946-65. Public Health Rep 1967, 82:1009-1018.
7. Noah D.L., Drenzek C.L., Smith J.S., et al. Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med 1998, 128:922-930.
8. Warrell M.J., Warrell D.A. Rabies and other lyssavirus diseases. Lancet 2004, 363:959-969.
9. Centers for Disease Control and Prevention Rabies prevention 2008, Centers for Disease Control and Prevention, Atlanta, GA.
10. Moran G.J., Talan D.A., Mower W., et al. Appropriateness of rabies postexposure prophylaxis treatment for animal exposures. Emergency ID Net Study Group. JAMA 2000, 284:1001-1007.
11. Centers for Disease Control and Prevention Cost of rabies prevention 2008, Centers for Disease Control and Prevention, Atlanta, GA.
12. Hemachudha T., Laothamatas J., Rupprecht C.E. Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 2002, 1:101-109.
13. King A.A., Meredith C.D., Thomson G.R. The biology of southern African lyssavirus variants. Curr Top Microbiol Immunol 1994, 187:267-295.
14. Rupprecht C.E., Gibbons R.V. Clinical practice. Prophylaxis against rabies. N Engl J Med 2004, 351:2626-2635.
15. Charlton K.M. The pathogenesis of rabies and other lyssaviral infections: recent studies. Curr Top Microbiol Immunol 1994, 187:95-119.
16. Leung A.K., Davies H.D., Hon K.L. Rabies: epidemiology, pathogenesis, and prophylaxis. Adv Ther 2007, 24:1340-1347.
17. Manning S.E., Rupprecht C.E., Fishbein D., et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008, 57:1-28.
18. Krebs J.W., Mandel E.J., Swerdlow D.L., et al. Rabies surveillance in the United States during 2004. J Am Vet Med Assoc 2005, 227:1912-1925.
19. Fekadu M. Canine rabies. Onderstepoort J Vet Res 1993, 60:421-427.
20. Schneider M.C., Belotto A., Ade M.P., et al. Current status of human rabies transmitted by dogs in Latin America. Cad Saude Publica 2007, 23:2049-2063.
21. Blanton J.D., Dyer J., McBrayer J., et al. Rabies surveillance in the United States during 2011. J Am Vet Med Assoc 2012, 241:712-722.
22. Gibbons R.V. Cryptogenic rabies, bats, and the question of aerosol transmission. Ann Emerg Med 2002, 39:528-536.
23. Bronnert J., Wilde H., Tepsumethanon V., et al. Organ transplantations and rabies transmission. J Travel Med 2007, 14:177-180.
24. Dietzschold B., Koprowski H. Rabies transmission from organ transplants in the USA. Lancet 2004, 364:648-649.
25. Hellenbrand W., Meyer C., Rasch G., et al. Cases of rabies in Germany following organ transplantation. Euro Surveill 2005, 10:E050224.6.
26. Messenger S.L., Smith J.S., Rupprecht C.E. Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis 2002, 35:738-747.
27. Jackson A.C. Rabies. Neurol Clin 2008, 26:717-726. ix.
28. Srinivasan A., Burton E.C., Kuehnert M.J., et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005, 352:1103-1111.
29. Feder H.M., Petersen B.W., Robertson K.L., et al. Rabies: still a uniformly fatal disease? Historical occurrence, epidemiological trends, and paradigm shifts. Curr Infect Dis Rep 2012, 14:408-422.
30. Rupprecht C.E., Hanlon C.A., Hemachudha T. Rabies re-examined. Lancet Infect Dis 2002, 2:327-343.
31. Nigg A.J., Walker P.L. Overview, prevention, and treatment of rabies. Pharmacotherapy 2009, 29:1182-1195.
32. Jackson A.C., Ye H., Phelan C.C., et al. Extraneural organ involvement in human rabies. Lab Invest 1999, 79:945-951.
33. Meslin F.X. Rabies as a traveler's risk, especially in high-endemicity areas. J Travel Med 2005, 12(Suppl 1):S30-S40.
34. Rupprecht C.E., Briggs D., Brown C.M., et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010, 59:1-9.
35. Johnson N., Cunningham A.F., Fooks A.R. The immune response to rabies virus infection and vaccination. Vaccine 2010, 28:3896-3901.
36. Jackson A.C. Rabies in the critical care unit: diagnostic and therapeutic approaches. Can J Neurol Sci 2011, 38:689-695.
37. Warrell D.A., Davidson N.M., Pope H.M., et al. Pathophysiologic studies in human rabies. Am J Med 1976, 60:180-190.
38. Novartis. RabAvert rabies vaccine [package insert] Emeryville, CA: 2006.
39. Sanofi Pasteur. Imovax rabies vaccine [package insert] Swiftwater, PA: 2012.
40. Fishbein D.B., Sawyer L.A., Reid-Sanden F.L., et al. Administration of human diploid-cell rabies vaccine in the gluteal area. N Engl J Med 1988, 318:124-125.
41. Verma R., Khanna P., Prinja S., et al. Intra-dermal administration of rabies vaccines in developing countries: at an affordable cost. Hum Vaccin 2011, 7:792-794.
42. WHO Expert Committee on Rabies. World Health Organ Tech Rep Ser 1992, 824:1-84.
43. Human rabies prevention-United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999, 48:1-21.
44. Briggs D.J., Dreesen D.W., Nicolay U., et al. Purified Chick Embryo Cell Culture Rabies Vaccine: interchangeability with Human Diploid Cell Culture Rabies Vaccine and comparison of one versus two-dose post-exposure booster regimen for previously immunized persons. Vaccine 2000, 19:1055-1060.
45. Ajjan N., Pilet C. Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells. Vaccine 1989, 7:125-128.
46. Arora A., Moeller L., Froeschle J. Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine. J Travel Med 2004, 11:195-199.
47. Sabchareon A., Lang J., Attanath P., et al. A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Clin Infect Dis 1999, 29:141-149.
48. Dreesen D.W., Fishbein D.B., Kemp D.T., et al. Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 1989, 7:397-400.
49. Deshpande A.K., Londhe V.A., Akarte S., et al. Comparative evaluation of immunogenicity, reactogenecity and safety of purified chick embryo cell rabies vaccine and neural tissue rabies vaccine. J Assoc Physicians India 2003, 51:655-658.
50. Fishbein D.B., Yenne K.M., Dreesen D.W., et al. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study. Vaccine 1993, 11:1390-1394.
51. Bernard K.W., Smith P.W., Kader F.J., et al. Neuroparalytic illness and human diploid cell rabies vaccine. JAMA 1982, 248:3136-3138.
52. Boe E., Nyland H. Guillain-Barré syndrome after vaccination with human diploid cell rabies vaccine. Scand J Infect Dis 1980, 12:231-232.
53. Cabasso V.J., Loofbourow J.C., Roby R.E., et al. Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull World Health Organ 1971, 45:303-315.
54. Talecris Biotherapeutics. HyperRAB S/D [package insert] Research Triangle Park, NC: 2010.
55. Sanofi Pasteur. Imogam rabies-HT [package insert] Swiftwater, PA: 2005.
56. Koprowski H., Van Der Scheer J., Black J. Use of hyperimmune anti-rabies serum concentrates in experimental rabies. Am J Med 1950, 8:412-420.
57. Dean D.J., Baer G.M., Thompson W.R. Studies on the local treatment of rabies-infected wounds. Bull World Health Organ 1963, 28:477-486.
58. Siber G.R., Werner B.G., Halsey N.A., et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 1993, 122:204-211.
59. Atkinson W.L., Pickering L.K., Schwartz B., et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002, 51:1-35.
60. Lang J., Gravenstein S., Briggs D., et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals 1998, 26:7-15.
61. LeGuerrier P., Pilon P.A., Deshaies D., et al. Pre-exposure rabies prophylaxis for the international traveller: a decision analysis. Vaccine 1996, 14:167-176.
62. Fishbein D.B., Arcangeli S. Rabies prevention in primary care. A four-step approach. Postgrad Med 1987, 82:83-90. 3-5.
63. Gautret P., Parola P. Rabies vaccination for international travelers. Vaccine 2012, 30:126-133.
64. Gautret P., Shaw M., Gazin P., et al. Rabies postexposure prophylaxis in returned injured travelers from France, Australia, and New Zealand: a retrospective study. J Travel Med 2008, 15:25-30.
65. Hatz C.F., Bidaux J.M., Eichenberger K., et al. Circumstances and management of 72 animal bites among long-term residents in the tropics. Vaccine 1995, 13:811-815.
66. Fishbein D.B., Bernard K.W., Miller K.D., et al. The early kinetics of the neutralizing antibody response after booster immunizations with human diploid cell rabies vaccine. Am J Trop Med Hyg 1986, 35:663-670.
67. Christian K.A., Blanton J.D., Auslander M., et al. Epidemiology of rabies post-exposure prophylaxis-United States of America, 2006-2008. Vaccine 2009, 27:7156-7161.
68. Krebs J.W., Long-Marin S.C., Childs J.E. Causes, costs, and estimates of rabies postexposure prophylaxis treatments in the United States. J Public Health Manag Pract 1998, 4:56-62.
69. Dreesen D.W., Bernard K.W., Parker R.A., et al. Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine. Vaccine 1986, 4:45-49.
70. WHO Expert Consultation on rabies. World Health Organ Tech Rep Ser 2005, 931:1-88.
71. Kaplan M.M., Cohen D., Koprowski H., et al. Studies on the local treatment of wounds for the prevention of rabies. Bull World Health Organ 1962, 26:765-775.
72. McDermid R.C., Saxinger L., Lee B., et al. Human rabies encephalitis following bat exposure: failure of therapeutic coma. CMAJ 2008, 178:557-561.
73. Khawplod P., Wilde H., Chomchey P., et al. What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously?. Vaccine 1996, 14:389-391.
74. Helmick C.G., Johnstone C., Sumner J., et al. A clinical study of Merieux human rabies immune globulin. J Biol Stand 1982, 10:357-367.
75. Wilde H., Sirikawin S., Sabcharoen A., et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis 1996, 22:228-232.
76. Rupprecht C.E., Briggs D., Brown C.M., et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009, 27:7141-7148.
77. Jenkins S.R., Auslander M., Conti L., et al. Compendium of animal rabies prevention and control, 2004. J Am Vet Med Assoc 2004, 224:216-222.
78. Thraenhart O., Marcus I., Kreuzfelder E. Current and future immunoprophylaxis against human rabies: reduction of treatment failures and errors. Curr Top Microbiol Immunol 1994, 187:173-194.
79. Smith J.S., Fishbein D.B., Rupprecht C.E., et al. Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med 1991, 324:205-211.
80. Helmick C.G. The epidemiology of human rabies postexposure prophylaxis, 1980-1981. JAMA 1983, 250:1990-1996.
81. Mahamat A., Meynard J.B., Djossou F., et al. Risk of rabies transmission and adverse effects of postexposure prophylaxis in health care workers exposed to a fatal case of human rabies. Am J Infect Control 2012, 40:456-458.
82. Kroger A.T., Atkinson W.L., Marcuse E.K., et al. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-48.
83. Varricchio F., Iskander J., Destefano F., et al. Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr Infect Dis J 2004, 23:287-294.
84. Enright J.B., Franti C.E., Frye F.L., et al. The effects of corticosteroids on rabies in mice. Can J Microbiol 1970, 16:667-675.
85. Pappaioanou M., Fishbein D.B., Dreesen D.W., et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986, 314:280-284.
86. Chutivongse S., Wilde H., Benjavongkulchai M., et al. Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants. Clin Infect Dis 1995, 20:818-820.
87. Recovery of a patient from clinical rabies-Wisconsin, 2004. MMWR Morb Mortal Wkly Rep 2004, 53:1171-1173.
88. Alvarez L., Fajardo R., Lopez E., et al. Partial recovery from rabies in a nine-year-old boy. Pediatr Infect Dis J 1994, 13:1154-1155.
89. Hattwick M.A., Weis T.T., Stechschulte C.J., et al. Recovery from rabies. A case report. Ann Intern Med 1972, 76:931-942.
90. Madhusudana S.N., Nagaraj D., Uday M., et al. Partial recovery from rabies in a six-year-old girl. Int J Infect Dis 2002, 6:85-86.
91. Porras C., Barboza J.J., Fuenzalida E., et al. Recovery from rabies in man. Ann Intern Med 1976, 85:44-48.
92. Willoughby R.E., Tieves K.S., Hoffman G.M., et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005, 352:2508-2514.
93. Jackson A.C., Warrell M.J., Rupprecht C.E., et al. Management of rabies in humans. Clin Infect Dis 2003, 36:60-63.
94. Warrell M.J., White N.J., Looareesuwan S., et al. Failure of interferon alfa and tribavirin in rabies encephalitis. BMJ 1989, 299:830-833.
95. Emmons R.W., Leonard L.L., DeGenaro F., et al. A case of human rabies with prolonged survival. Intervirology 1973, 1:60-72.
96. Hattwick M.A., Corey L., Creech W.B. Clinical use of human globulin immune to rabies virus. J Infect Dis 1976, 133(Suppl):A266-A272.
97. Kureishi A., Xu L.Z., Wu H., et al. Rabies in China: recommendations for control. Bull World Health Organ 1992, 70:443-450.
98. Merigan T.C., Baer G.M., Winkler W.G., et al. Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Ann Neurol 1984, 16:82-87.
99. Hemachudha T., Sunsaneewitayakul B., Desudchit T., et al. Failure of therapeutic coma and ketamine for therapy of human rabies. J Neurovirol 2006, 12:407-409.
100. Lockhart B.P., Tordo N., Tsiang H. Inhibition of rabies virus transcription in rat cortical neurons with the dissociative anesthetic ketamine. Antimicrob Agents Chemother 1992, 36:1750-1755.